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Alternative cleavage and polyadenylation (APA) is
emerging as an important layer of gene regulation.
Factors controlling APA are largely unknown. We
developed a reporter-based RNAi screen for APA
and identified PABPN1 as a regulator of this process.
Genome-wide analysis of APA in human cells
showed that loss of PABPN1 resulted in extensive
30 untranslated region shortening. Messenger RNA
transcription, stability analyses, and in vitro cleavage
assays indicated enhanced usage of proximal
cleavage sites (CSs) as the underlying mechanism.
Using Cyclin D1 as a test case, we demonstrated
that enhanced usage of proximal CSs compromises
microRNA-mediated repression. Triplet-repeat ex-
pansion in PABPN1 (trePABPN1) causes autosomal-
dominant oculopharyngeal muscular dystrophy
(OPMD). The expression of trePABPN1 in both a
mouse model of OPMD and human cells elicited
broad induction of proximal CS usage, linked to
binding to endogenous PABPN1 and its sequestra-
tion in nuclear aggregates. Our results elucidate
a novel function for PABPN1 as a suppressor of APA.
INTRODUCTION
The addition of an adenine tail (poly(A)) to messenger RNA
(mRNA) 30 ends is a cotranscriptional nuclear process that is
important for nuclear export, translation, andmRNA stability (Le-
may et al., 2010). mRNA polyadenylation is a two-step process
consisting of an endonucleolytic cleavage and addition of an un-
templated poly(A) tail. Adjacent cis-acting motifs direct cleavage
position and efficiency. Mainly, an upstream hexamer polyade-
nylation signal (PAS) and a downstream UG-rich sequence538 Cell 149, 538–553, April 27, 2012 ª2012 Elsevier Inc.recruit the cleavage and polyadenylation specificity factor
(CPSF) and the cleavage-stimulating factor (CSTF), respectively,
both required for the polyadenylation process (Bentley, 2005;
Zhang et al., 2010). The canonical PAS is AAUAAA, which
appears in about half of the cleavage sites (CSs). More than
ten variants of the canonical PAS have been reported, and the
most prominent among them is AUUAAA (Beaudoing et al.,
2000; Tian et al., 2005).
mRNA poly(A) tails are added by a highly evolutionary con-
served poly(A) polymerase (PAP) and recruit poly(A)-binding
proteins (PABPs), which come in two flavors, the cytosolic
PABPC and the nuclear PABPN1. The nuclear PABPN1 is
structurally and functionally different from PABPC and is
thought to function during poly(A) tail addition to mRNAs.
In vitro, efficient polyadenylation requires CPSF, PAP, and
PABPN1 (Ku¨hn et al., 2009; Wahle, 1995). Whereas CPSF
binds to PAS to cleave mRNAs and modestly stimulates polya-
denylation, PABPN1 addition to CPSF/PAP strongly stimulates
polyadenylation.
Most mammalian mRNAs contain a 30 untranslated region
(30 UTR) that plays a key role in regulating mRNA stability, local-
ization, and translation efficiency (Andreassi and Riccio, 2009;
Fabian et al., 2010). These functions are mediated mostly
through binding of microRNAs (miRNAs) and RNA-binding
proteins (RBPs) to regulatory elements embedded in the target
30 UTRs. miRNAs are small, noncoding RNAs that guide miRNP
complexes to 30 UTRs by sequence-specific interaction with 30
UTRs based on a 6–8 seed sequence at their 50 ends (Fabian
et al., 2010). miRNAs are predicted to target the majority of
human protein-coding genes, enabling them to play numerous
regulatory roles in many physiological and developmental pro-
cesses (Kedde and Agami, 2008). RBPs, like miRNAs, are key
components in gene expression regulation. They can either
bind specific sequence elements on mRNAs (e.g., the human
Pumilio RBP family) or looser consensus sequences, such as
U- and A/U-rich motifs, to control expression in a negative or
positive manner (Filipowicz et al., 2008). Moreover, RBPs can
bind 30 UTRs and interfere or stimulate miRNA function (Kedde
et al., 2007, 2010). Thus, it appears that 30 UTRs can be viewed
as regulatory platforms that determine mRNA stability, subcel-
lular localization, and rate of protein synthesis (van Kouwenhove
et al., 2011).
The number of human and mouse genes reported to use alter-
native cleavage and polyadenylation (APA) to generate multiple
mRNA isoforms with different 30 UTR lengths is continuously
increasing and already passes the 50% estimate (Fu et al.,
2011; Jan et al., 2011; Lutz, 2008; Ozsolak et al., 2010; Shepard
et al., 2011; Tian et al., 2005). Therefore, APA is emerging as an
important layer in gene regulation as it modulates the inclusion of
target sites for miRNAs and RBPs in 30 UTRs. Already more than
a decade ago, it was shown that changes in the concentration of
CstF could affect APA of IgM heavy-chain transcripts during B
cell development (Takagaki and Manley, 1998; Takagaki et al.,
1996). Recently, it was observed that whereas primary human
cells mostly use distal PASs, usage of proximal sites, which
results in 30 UTR shortening, is enhanced during cell activation
(Sandberg et al., 2008), early in development (Ji et al., 2009),
and in cancer (Mayr and Bartel, 2009; for a recent review, see
Di Giammartino et al., 2011). However, factors that regulate
APA during cancer progression and differentiation are still largely
unknown.
Oculopharyngeal muscular dystrophy (OPMD) is an auto-
somal-dominant form of late-onset (patients aged >40 years),
slowly progressive myopathy, characterized by bilateral eyelid
ptosis (drooping), dysphagia (swallowing difficulties), and prox-
imal limb weakness (Ru¨egg et al., 2005). Beyond the age of 70,
all patients are symptomatic. OPMD was reported in >30 coun-
tries worldwide, with a low estimated occurrence that can be as
high as 1:600 in specific communities (Blumen et al., 1997).
OPMD is caused by short expansions of a (GCG)6 triplet repeat
to (GCG)8–13 in the PABPN1 gene (trePABPN1), which results
in the expansion of a polyalanine stretch from 10 to 12–17
alanines in the amino terminus of the protein (Brais et al.,
1998). Disease mutant (mut) trePABPN1 induces nuclear protein
aggregation and forms filamentous nuclear inclusions, a patho-
logical hallmark of OPMD (Calado et al., 2000; Thome´ et al.,
1997). How the triplet-expansion mutations affect PABPN1
activity and cellular behavior is currently unknown. To study
OPMD, a transgenic mouse model was developed that
expresses mut trePABPN1(A17) under the control of the
muscle-specific human skeletal actin promoter (Davies et al.,
2005). trePABPN1(A17) mice appear normal at birth but develop
a progressive muscle weakness that is accompanied by the
formation of trePABPN1(A17)-containing aggregates in the nuclei
of skeletal myocytes and by accelerated apoptosis (Davies and
Rubinsztein, 2011; Davies et al., 2005).
Here, using a wide-scale RNAi screen focused on human
RBPs, we identified PABPN1 as a suppressor of APA. Loss of
PABPN1 resulted in a global enhancement of proximal CSs
usage in independent human cellular systems. In amousemodel
for OPMD, as well as in human cells, the expression of a disease
mut trePABPN1(A17) also resulted in an extensive enhancement
of proximal CSs. Our results elucidate a role for PABPN1 in sup-
pressing APA sites and predict a role for unbalanced APA in
OPMD.RESULTS
AnRNAi Screen Identifies PABPN1as aRegulator of APA
We designed a reporter system (named pSTAR; a plasmid
system to identifyAPA regulators) to identify factors that regulate
the usage of APA sites. We cloned downstream to the Renilla
luciferase in psiCHECK2 (psiC) an 1 kb region of the 30 UTR
of the mixed leukemia lymphoma gene (MLL), recently discov-
ered to strongly repress luciferase expression, mainly at the
level of RNA synthesis (Figures 1A; Figure S1A available online;
Gomez-Benito et al., 2011). Physical engagement of RNA poly-
merase (Pol) II with transcription of this MLL region results in
repression and low luciferase counts. Next, we cloned the prox-
imal alternative PAS region of Cyclin D2 (CCND2; Mayr and
Bartel, 2009) upstream of the MLL insert and used the mutated
PAS as control (pSTAR-D2WT, pSTAR-D2mut; Figures 1A, S1A,
and S1B). We expected that the Renilla luciferase repression
by MLL-30 UTR in pSTAR would be weakened due to early
cleavage mediated by the CCND2 PAS in pSTAR-D2WT. Figures
1A and S1C show that the MLL-30 UTR repressor reduced the
Renilla/Firefly (R/F) ratio by more than 10-fold by lowering the
Renilla luciferase expression. As expected, the insertion of
CCND2 wild-type (WT) proximal PAS significantly relieved the
repression, and this relief was less effective when that PAS
was mutated (Figure 1A). Sequence analysis of transcript ends
downstream of the Renilla gene in pSTAR-D2WT revealed the
exact expected CS (Figure S1B). Similar effects were observed
with the p27 (CDKN1B) 30 UTR distal PAS region (Figures 1B
and S1D), albeit this PAS showed a stronger effect, which is
consistent with it being the strongest functional PAS of the p27
gene (Figures 1B and S4C). Therefore, in both cases our pSTAR
reporter system successfully monitored PAS activity.
Next, we performed an RNA interference (RNAi) library screen
to identify RBPgenes required for APA.We reasoned that knock-
ing down genes involved in APA should attenuate the difference
in R/F ratios measured for the WT and mutant proximal CCND2
PAS constructs. Thus, we transfected pSTAR-D2WT and -D2mut
into U2OS cells and reverse transfected siRNA smart pools de-
signed to target 489 RBP genes (Figure S1E). The R/F ratio of
pSTAR-D2WT was compared to that of -D2mut (Figure 1C). Genes
were ranked according to the relative difference between R/F
ratios for pSTAR-D2WT and -D2mut (Table S1). The top-scoring
candidate in this screen (i.e., the candidate that minimized the
gap between pSTAR-D2WT and -D2mut) was PABPN1 (Figure 1C,
red point). To validate this result, we tested each individual small
interfering RNA (siRNA) from the PABPN1 smart pool. All four
siRNAs effectively silenced PABPN1 expression and diminished
the difference between pSTAR-D2WT and -D2mut (Figures 1E
and 1D). siRNA #1 and #2 were the most efficient ones. This
effect of PABPN1 knockdown (kd) was confirmed at the mRNA
level (Figure S1F). Detailed examination of the effect of PABPN1
kd showed that in addition to its effect on the relative pSTAR-
D2-WT/mut counts, it also lowered the basal R/F ratio (Figure 1E).
However, the latter effect was observed also in the control
pSTAR vector (Figure 1F, upper panel), indicating it is not related
to PABPN1’s role in regulating the usage of the CCND2-PAS
insert. Intriguingly, the attenuation of the gap between pSTAR-
D2WT and -D2mut caused by PABPN1 kd did not result fromCell 149, 538–553, April 27, 2012 ª2012 Elsevier Inc. 539
Figure 1. Functional Genetic Screen Identifies PABPN1 as a Regulator of PAS Usage
(A) Our pSTAR system consists of psiCHECK2 (psiC) dual luciferase vectors (Figure S1A), containing the WT or mut proximal CCND2 PAS (D2WT or D2mut;
Figure S1B) upstream of the MLL-30 UTR fragment (240–1143 bp; named repressor [R]). These systems were transfected into U2OS cells for 72 hr. The relative
R/F ratio (average ± standard deviation [SD]) was determined.
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a compromised relief of the Renilla luciferase repression in the
pSTAR-D2WT construct: in PABPN1 kd cells, the R/F ratio
between pSTAR-D2WT and pSTAR (7.0) was similar to the control
(5.5; Figures 1F, upper panel and 1G). Instead, in the absence of
PABPN1, the effect of pSTAR-D2mut on the repression relief was
markedly reduced (Figures 1F, upper panel and 1G). As an indi-
cation for the specificity of PABPN1-mediated regulation of APA,
no major effect of PABPN1 kd was observed on the stronger
distal p27-PAS (Figure 1F, middle panel; PABPN1 kd confirmed
by quantitative reverse transcription-polymerase chain reaction
[qRT-PCR]; lower panel) nor on the proximal FGF2 and Dicer1
PASs (Figure S1G). To further ascertain PABPN1’s involvement
in the regulation of CCND2-PAS usage, we constructed
siRNA-resistant PABPN1 expression vectors for siRNAs #1
and #2. Expression of the siRNA-resistant PABPN1 proteins
restored in the presence of PABPN1 siRNAs #1 and #2 the differ-
ence in R/F ratio of WT versus mut CCND2-PAS to levels
observed by WT PABPN1 overexpression (Figure 1H). We
confirmed PABPN1 kd and reconstitution by siRNA-resistant
constructs with immunoblotting (Figure 1I). Altogether, our
results indicate that in the absence of PABPN1, early cleavage
occurred efficiently in both the pSTAR-D2WT and -D2mut
constructs, suggesting that loss of PABPN1 activated a dormant
CS in the CCND2-proximal PAS region to mediate an early
cleavage in the mut PAS construct.
Loss of PABPN1 Induces Global 30 UTR Shortening
To examine the role of PABPN1 in PAS selection on a global
scale, we applied a deep-sequencing-based technique adapted
from Beck et al. (2010) and named 30Seq (Figure S2A). 30Seq
allows precise mapping of 30-end cleavage and poly(A) sites at
a nucleotide resolution based on the alignment of sequenced
reads that span the CS and therefore cover the beginning of
the untemplated poly(A) tail (Figures S2B and S2C). We applied
30Seq to four independent U2OS-transfected control and two
PABPN1 kd samples. Analyzing the 30Seq dataset, we identified
23,635 CSs, of which 58% mapped to 30 UTRs of 9,345 tran-
scripts (Figure S2D). 2,990 (32%) transcripts contained more
than one CS in their 30 UTR (Figure S2E). We benchmarked these
CSs against annotated CSs recorded in the poly(A) database
(Lee et al., 2007) or in Ozsolak et al. (2010) and found 11,407
(83%) of the 30 UTR CSs to overlap with at least one of these
resources but only 2,227 (22%) of other CSs (Figure S2F). There-
fore, in subsequent analyses, we included only CSs that mapped(B) Same experiments as in (A), but a region encompassing the p27-PAS (p27WT
(C) U2OS cells were transfected with pSTAR-D2WT and -D2mut constructs, reverse
Figure S1E). Standardized differences between log2 of R/F ratios measured in
PABPN1 kd (in red) strongly minimized the gap between pSTAR-D2WT and -D2m
(D and E) The four individual siRNAs of the PABPN1 smart pool used in (C) were
relative to b-actin). (E) shows relative R/F ratios (average ± SD) for pSTAR-D2WT
(F) pSTAR-D2WT and -D2mut were transfected into U2OS cells. After 16 hr, cells we
ratios were determined (mean ± standard error of the mean [SEM]; upper and mid
by qRT-PCR.
(G) Quantification of the R/F ratios shown in (F) for WT and mut CCND2-PAS (n =
(H) In addition to the reporter constructs used in (F) (upper panel), expression
cotransfected. Data are represented as average ± SD.
(I) Immunoblot analysis with PABPN1 and b-actin antibodies of whole-cell extrac
See also Figure S1 and Table S1.to 30 UTRs. We next searched for enriched sequence motifs in
the region of ±50 nt with respect to the CSs. The most enriched
signal in this region was the canonical AAUAAA PAS (corre-
sponding to AATAAA on the DNA level). Also, all major variants
of the canonical signal (Tian et al., 2005) were highly enriched
too, with AUUAAA being the second most prominent motif,
appearing together with the canonical signal in 60% of the
mapped CSs (Figure S2G). As an additional indication for the
precision of the CS mapping by 30Seq, the location distribution
of the major PAS signals showed a sharp peak at the docu-
mented position 20 nt upstream of the CSs (Figure S2H) (Tian
et al., 2005). De novo motif discovery analysis also detected
enriched T/TG motifs, which, in accordance with previous
reports (Hu et al., 2005; Lutz, 2008; Nunes et al., 2010), peaked
downstream of the CSs (Figure S2I).
Next, we examined the effect of PABPN1 kd on PAS selection.
We identified 572 transcripts that showed a significant shift in
CS usage in PABPN1 kd versus control samples (p < 0.001;
chi-square test; Table S2A). In more than 90% of these tran-
scripts, the shift in CS usage was toward the proximal PASs
(p < 1099; binomial tail), indicating an extensive 30 UTR short-
ening in the absence of PABPN1 (Figures 2A and 2B). We vali-
dated by quantitative polymerase chain reaction (qPCR) and
northern blot the increase in the level of the short relative to
the long isoform for selected genes (Figures 2C and S2M). The
northern blot showed for the majority of the examined genes
that PABPN1 kd results in elevated (absolute) levels of the short
isoform, indicating that the increase in the short/long ratio in the
absence of PABPN1 was associated with enhanced cleavage
at the proximal PASs (Figure S2M, right panel). To quantify the
relative usage of each PAS in a transcript, we defined the PAS
usage index (PUI; Extended Experimental Procedures). Compar-
ison of the proximal PUI distribution in PABPN1 kd versus control
samples further demonstrated the significantly enhanced usage
of proximal PASs in the absence of PABPN1 (Figures 2D and 2E).
To confirm the effect of PABPN1 kd on PAS selection, we
applied 30Seq to a second cell line (RPE-1). Here too, PABPN1
kd resulted in a broad 30 UTR shortening (Figures S2N–S2P).
Of the 357 transcripts with a significant shift in CS usage, 291
(82%) showed 30 UTR shortening in the PABPN1 kd samples
(p = 3.97 * 1035) (Figure S2Q).
These results strongly suggest that PABPN1 kd causes a
significant shift toward proximal PAS usage. Therefore, we
sought to identify sequence features that potentially differand p27mut; Figure S1D) was used.
transfected with siRNA smart pools targeting 489 RBP genes (384-well format;
the pSTAR-D2WT and -D2mut constructs are shown for each targeted gene.
ut.
reverse transfected. (D) shows the relative PABPN1 mRNAs levels (qRT-PCR;
and -D2mut in the individual siRNA samples.
re reverse transfected with the indicated siRNAs. Seventy-two hours later, R/F
dle panels). Lower panel: PABPN1 mRNA levels in transfected cells measured
15; mean ± SEM; one-tailed t test).
vectors for empty control, PABPN1 WT, or siRNA-resistant PABPN1 were
ts (WCE) from the cell populations used in (H).
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Figure 2. PABPN1 kd Induces Extensive 30 UTR Shortening
(A) Examples of transcripts showing significant 30 UTR shortening, manifested by a prominent increase in the proximal CS level relative to the distal one in
PABPN1 kd compared to control samples. Transcripts with red-colored reads are encoded on the reverse DNA strand, thus the distal CS is on the left and the
proximal CS is on the right side.
542 Cell 149, 538–553, April 27, 2012 ª2012 Elsevier Inc.
between proximal and distal sites. Analyzing the set of tran-
scripts containing exactly two 30 UTR CSs, we found a signifi-
cantly higher prevalence of the canonical PAS, but not of its
variants, in distal versus proximal sites (49% versus 27%,
respectively; Table S3). This difference was even more pro-
nounced in the subset of transcripts, which showed significant
30 UTR shortening in the PABPN1 kd samples (Table S3), sug-
gesting that PABPN1 kd enhances the usage of noncanonical
proximal PASs.
Loss of PABPN1 Enhances mRNA Cleavage Mediated
by Proximal PASs
PABPN1 kd significantly increased the usage of proximal CSs
relative to distal ones in hundreds of transcripts, and for several
transcripts, a clear upregulation of the short form was observed
by northern blots (Figure S2M). However, it is possible that
PABPN1 kd globally destabilized transcript isoforms with longer
30 UTRs (e.g., due to broad activation of miRNA activity or RBPs).
To examine this possibility, we measured the stability of short
and long transcript isoforms for several genes that showed
a significant shift toward the proximal PAS in PABPN1 kd
samples. We used 30-end qRT-PCR to distinguish between the
stability of isoforms with short and long 30 UTRs (generated by
cleavage at proximal and distal CSs, respectively). To check
the validity of the 30-end qRT-PCR method, we first examined
the relatively unstable p27 transcript. Standard qRT-PCR
measurement of p27 mRNA stability showed that p27 mRNA
fromU2OS cells has a half-life of2 hr (Figure 3A). No significant
change in p27 stability was observed in PABPN1 kd cells (Fig-
ure 3A). When the same total RNA samples were examined
with 30-end qRT-PCR covering the p27-PAS sequence, similar
p27 stability was found, and again no significant effect of
PABPN1 kd was seen (Figure 3B, left panel). 30-end qRT-PCR
applied to b-actin mRNA expectedly revealed a highly stable
transcript (Figure 3B, right panel). Thus, stability estimates ob-
tained by 30-end qRT-PCR agree with those obtained with stan-
dard qRT-PCR. Moreover, PABPN1 kd did not significantly
change the stability of these two single PAS-containing genes.
Next, we applied 30-end qRT-PCR to compare the stability of
the long and short 30 UTR transcript isoforms of PSMD8,
SUPT6H, PDRG1, E2F1, and CCND1 that showed a strong shift
toward the proximal PAS following PABPN1 kd. Regardless of
the stability of the 30 end observed in control cells (e.g.,
PSMD8 is highly stable, whereas PDRG1 is relatively unstable),
PABPN1 kd had no significant effect on the stability of all five
transcripts (Figures 3C, 4D, and S3A). qRT-PCR demonstrated(B) Five hundred and seventy-two transcripts showed a significant shift (p < 0.0
tween PABPN1 kd and control samples. In 523 of these transcripts, absence o
resulting in overall 30 UTR shortening. (p value calculated using binomial tail.)
(C) To confirm the results of the 30Seq, the same samples as in (B) were sub
average ± SD.
(D) Comparison between the distribution of the PUI of the proximal sites in the PAB
PABPN1 kd resulted in a global increase of proximal PAS usage (p value was c
showed significant shift in CS usage.
(E) Themedian of the proximal sites PUI distribution, calculated over all transcripts
proximal CSs in each sample. PABPN1 kd resulted in a marked increase in this
See also Figure S2 and Tables S2A and S3.an efficient PABPN1 kd (Figure 3D). We conclude that a global
destabilization of longer transcripts is not a major cause of the
broad shift toward proximal PASs observed in the absence of
PABPN1.
Next, we examined the transcription along MAPKAPK3,
PDRG1, and E2F1, which showed significantly elevated usage
of the proximal relative to the distal CS in PABPN1 kd cells. If
proximal PAS usage is indeed activated, reduced levels of Pol
II occupancy should be detected in the 30 UTR downstream of
the proximal PAS following loss of PABPN1 expression.
Conversely, if destabilization of the longer transcript causes
the relative increase in the usage of the proximal versus the distal
PAS, no change in Pol II levels along the 30 UTR should be
observed in PABPN1 kd samples. Chromatin immunoprecipita-
tion (ChIP) from extracts of control and PABPN1 siRNA-trans-
fected cells showed that for these genes, but not for p27 (nega-
tive control), PABPN1 kd significantly reduced Pol II interaction
with distal 30 UTRs relative to coding sequence (CDS) (Figure 3E).
This indicates an early termination of Pol II transcription in the
absence of PABPN1 and supports the conclusion that a reduced
level of PABPN1 results in activation of proximal CSs.
PABPN1 Regulation of Proximal CSs
The extensive activation of proximal CSs in the absence of
PABPN1 can result from enhanced activity of the pre-mRNA
30-end processing machinery. A recent study identified >90
proteins that constitute this processing complex (Shi et al.,
2009). Global upregulation of the set of genes encoding these
factors accompanies the broad 30 UTR shortening observed
during enhanced cellular proliferation (Ji et al., 2009 and unpub-
lished data). To examine whether a similar induction of 30-end
processing genes underlies the 30 UTR shortening in the absence
of PABPN1, we used the 30Seq data to derive gene expression
estimates and compared the expression of these genes between
control and PABPN1 siRNA-transfected U2OS cells. However,
no global change in the expression of genes involved in the
30-end processing was detected in PABPN1 kd samples (Fig-
ure S3B). This indicates that the absence of PABPN1 does not
activate proximal CSs through global induction of the 30-end
processing machinery.
Another possible explanation for activated proximal CS usage
in the absence of PABPN1 is a direct interaction of PABPN1 with
proximal PAS regions, which are typically weaker than distal
signals. Such binding of PABPN1may compete with PAS recog-
nition and/or mRNA cleavage complexes and thus can reduce
cleavage efficiency at these sites. To examine this model, we01; chi-square test; see Extended Experimental Procedures) in CS usage be-
f PABPN1 enhanced the usage of the proximal site relative to the distal one,
jected to qRT-PCR. Results were normalized to siControl #1 and shown as
PN1 kd and control samples. The significant shift to the right demonstrates that
alculated using Wilcoxon test). The analysis included the 572 transcripts that
with more than one 30 UTR CS, was taken as a global measure for the usage of
measure.
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tested PABPN1 interaction with proximal PAS regions in vivo.
We immunoprecipitated PABPN1 from U2OS cells that were
subjected to 4-thiouridine and ultraviolet (UV) crosslinking
treatments. Then we performed qRT-PCR with reverse oligos
immediately downstream of the proximal CSs of SUPT6H, MAP-
KAPK3, and hnRNPUL2 in order to distinguish unprocessed
transcripts from cleaved and polyadenylated isoforms (Fig-
ure S3C). Such primer setting is essential because PABPN1
strongly associates with poly(A) tails inside nuclei, and this
binding may overshadow PABPN1 binding to regions adjacent
to proximal CSs. As control for the specificity of the PABPN1
binding, we used qRT-PCR primers mapping to coding regions
(Figure S3C). The proximal PAS regions of all three genes exam-
ined were significantly enriched for PABPN1 binding (Figure 3F).
We then examined whether PABPN1 binds to proximal PAS
regions in vitro. We synthesized the proximal hnRNPUL2 PAS
including 30 nt down- and upstream and used RNA-electromo-
bility shift assays (R-EMSA) to examine the binding of recombi-
nant PABPN1 (rPABPN1) to this radiolabeled proximal PAS
region (Ku¨hn et al., 2009). We observed rPABPN1 binding that
was largely dependent on the integrity of the PAS sequence,
as mutating the triple A of the PAS to triple C clearly reduced
rPABPN1 binding to this region (Figure 3G). rPABPN1 binding
to the WT PAS region was efficiently competed with cold WT,
but not mutated, PAS sequence (Figure 3H). This indicates
specific binding to the PAS region. Similar results were obtained
with the proximal MAPKAPK3 PAS region and increasing
rPABPN1 amounts (Figures 3I and S3D). These results suggest
a direct effect of PABPN1 on proximal PAS usage.
Next, we performed in vitro cleavage assays to test whether
PABPN1 directly regulates PAS-mediated cleavage. We used
in vitro synthesized RNA probes comprising the proximal PAS
regions of MAPKAPK3, hnRNPUL2, and SUPT6H and the distal
PAS region of MAPKAPK3. In these probes, the CS of the
MAPKAPK3 distal PAS region is located 10 nt from the 30 end,
and the CSs of MAPKAPK3, hnRNPUL2, and SUPT6H proximal
PAS regions at 25–30 nt from the 30 end (Figure S3E). As
controls, we used probes with mutated PAS sequence (AAA to
CCC, designated WT to mut). When incubating these probesFigure 3. PABPN1 Regulation of Proximal CSs
(A and B) U2OS cells were transfected with PABPN1 siRNAs (kd #1 and #2) fo
measured by standard qRT-PCR for p27-CDS (A) or by 30-end qRT-PCR for p27
(C) The stability of mRNA isoforms terminated at the distal CS was measured by
a destabilization of the longer transcript or in a stabilization of the shorter isofom
(D) qRT-PCR was performed to check PABPN1 kd in the same samples as in (A
(E) Pol II ChIPs from extracts of U2OS cells transfected with control or PABPN1 siR
and in CDS (mean ± SEM; one-tailed t test). Lower panel: schematic location of
(F) WCE of 4-thiouridine-treated and UV-crosslinked U2OS cells were immunopre
(primers: Figure S3C). Relative enrichment of PABPN1 over IgG was determined
(G) R-EMSA performed with RNA oligonucleotides encompassing 30 nt up- and
bacterial rPABPN1 was used.
(H) WT hnRNPUL2 PAS oligonucleotides were competed with increasing amount
hnRNPUL2 PAS was efficiently competed with cold WT oligonucleotide but not
(I) R-EMSA performed with RNA oligonucleotides surrounding the proximal WT o
(J) In vitro cleavage assays with probes encompassing the proximal MAPKAPK3,
nuclear extracts from HeLa cells transfected with control (C) or PABPN1 (#2) siR
mented with 50 nM rPABPN1, respectively). The arrowmarks the cleaved product
levels (average ± SD) and a western blot of PABPN1 (same HeLa nuclear extrac
See also Figure S3.with nuclear extract of HeLa cells transfected with control
siRNAs (Figure 3J, lane C), we observed efficient and specific
cleavage of the canonical distal MAPKAPK3 region but very
limited cleavage of the proximal PAS regions. PABPN1 kd (#2)
enhancedcleavageof all proximal probesbut not of thecanonical
distal one. As no cleavage products of proximal or distal probes
were seen when the control PAS mut probes were used, and
as the lengths of the cleavage products fit the expected sizes
(Figure S3E), we conclude that this cleavage is mediated by the
30-end processingmachinery and that loss of PABPN1 enhances
it. Supporting this notion, adding rPABPN1 to the cleavage reac-
tion markedly reduced PABPN1-induced cleavage efficiency
(Figure 3J, lane #2+P). PABPN1 kd was confirmed by qRT-PCR
and western blotting (Figure 3J, upper right corner). This result
strongly supports a direct role for PABPN1 in suppressing PAS-
mediated cleavage at proximal sites.
PABPN1 Contributes to Efficient 30 UTR-Mediated
Repression
Loss of PABPN1 in U2OS cells increased the usage of CCND1
proximal PAS by 2-fold (Figures 4A–4C). This shift was not
accompanied by any stability changes of the long or the short
transcript isoforms (Figure 4D). CCND1 is a target of the miR-
17-19 cluster (Figure 4E), which is expressed in U2OS cells (Fig-
ure 4F). Thus, we examined whether loss of PABPN1 attenuates
CCND1 sensitivity to miR-17-19. We transfected U2OS cells
with a construct containing the miR-17-19 cluster (miRVec-17-
19, expressing miR-17, -18a, -20a, -19a, and -19b-1; Fig-
ure S4A), or a control vector, and reverse transfected these cells
with control and PABPN1 #1 and #2 siRNAs. Transfection of
miRVec-17-19 increased miR-20a levels and suppressed
CCND1 protein expression in control but not in PABPN1
siRNA-transfected cells (Figures 4F and 4G). To further examine
the PABPN1 effect on miR-17-19-mediated repression of the
CCND1 30 UTR, we constructed dual luciferase vectors contain-
ing either the full-length CCND1 30 UTR (psiC-D1-FL) or a short
CCND1 30 UTR that terminates at the proximal CS (psiC-D1-S).
The transfection of miRVec-17-19 resulted in 3.5-fold relative
inhibition of the full-length CCND1 30 UTR compared tor 72 hr and incubated with actinomycin D (ActD) for 6 hr. mRNA levels were
-PAS and b-Actin PAS (B). Data are shown as average ± SD.
30-end qRT-PCR (average ± SD). In none of the cases did PABPN1 kd result in
s (Figure S3A).
), (B), and (C). Data are shown as average ± SD.
NAs. Pol II binding wasmeasured in 30 UTRs downstream of the proximal PAS
the primers.
cipitated with PABPN1 or control IgG antibody, and qRT-PCR was performed
(mean ± SEM; one-tailed t test).
downstream of the proximal WT or mut hnRNPUL2 PAS. Fifty nanomolar of
s of cold WT or mut hnRNPUL2 PAS oligonucleotides. rPABPN1 binding to WT
with the mut oligonucleotide.
r mut MAPKAPK3 PAS and increasing rPABPN1 amounts.
hnRNPUL2, and SUPT6H PASs and the distal MAPKAPK3 PAS, incubated with
NAs ( and +P: probes incubated without nuclear extract or extracts supple-
s. Upper right corner: qRT-PCR showing the relative PABPN1 to b-actin mRNA
ts as used for the cleavage assay). BG: background band.
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Figure 4. PABPN1 kd Induces CCND1 Proximal PAS Usage and Reduces Its Targeting by miRNAs
(A) A UCSC web browser screenshot showing the shift in PAS usage of CCND1 in PABPN1 kd cells.
(B) The ratios of proximal to distal peak area shown in (A), normalized to the average of the four controls.
(C) qPCR with cDNA from (A) (average ± SD).
(D) 30-end qRT-PCR to measure the stability of the mRNA isoforms generated using the proximal and the distal CCND1 PAS. Data are shown as average ± SD.
(E) A scheme of the CCND1 30 UTR, proximal and distal PASs, and conserved target sites for miR-17/20a, 19, and 15/16 and let-7 (targetscan; Grimson
et al., 2007).
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miRvec-Ctrl transfection (Figure S4B, left panel). Moreover,
whereas the full-length CCND1 30 UTR was highly repressed
by miR-17-19, the short CCND1 30 UTR form was completely
resistant (Figure S4B, left panel). PABPN1 kd significantly
reduced miR-17-19 effect on the full-length construct (p <
0.00001; one-tailed t test; Figure 4H, left panel). To control for
general effects on miRNA activity, we used p27 30 UTR that
showed no APA in our dataset (Figure S4C) and contained
two miR-222 target sites (le Sage et al., 2007). We cotransfected
the psiC-p27 30 UTR with miRVec-222 and observed an 2-fold
relative inhibition of p27 30 UTR compared to miRvec-Ctrl trans-
fection (Figure S4B, right panel). A construct containing muta-
tions in the two miR-222 target sites (p27-30 UTR-DM) was resis-
tant to miR-222-mediated suppression (Figure S4B, right panel).
In contrast to CCND1, PABPN1 kd did not affect miR-222-
mediated repression of p27 30 UTR (Figure 4H, right panel), indi-
cating that PABPN1 does not generally interfere with miRNA
function in our system. These results provide an example for
the role of PABPN1 in suppressing proximal PAS usage, thereby
allowing the regulation of the target gene by its full 30 UTR
sequence.
Extensive 30 UTR Shortening Caused by an OPMD-
Associated PABPN1 Mutant
Short triplet-repeat expansion mutations in the PABPN1 gene
(trePABPN1) cause the autosomal-dominant OPMD disease.
As the effect of trePABPN1 on the function of the endogenous
WT PABPN1 protein is unknown, we examined whether tre-
PABPN1(A17) interacts with endogenous WT PABPN1. We mildly
expressed a GFP-tagged trePABPN1(A17) in U2OS cells and de-
tected nuclear dots with immunostaining (Figure 5A, marked
with #). Immunohistochemistry with PABPN1 antibody revealed
a colocalization of endogenous PABPN1 with GFP-tre-
PABPN1(A17) dots in transfected cells (#), whereas a rather
homogenous staining in untransfected cells was seen (Figure 5A,
marked with arrows). This suggests that trePABPN1(A17) seques-
ters endogenous PABPN1. If this effect is direct, one
should expect binding of trePABPN1(A17) to PABPN1. Indeed,
coimmunoprecipitation reveals interaction between GFP-tre-
PABPN1(A17) and endogenous WT PABPN1 (Figure 5B, lane 6).
Next, we examined whether trePABPN1(A17) also affects APA,
as we found that loss of WT PABPN1 significantly induced the
usage of proximal PASs. We transfected U2OS cells with an
expression vector for trePABPN1(A17) or a control vector and
performed 30Seq. trePABPN1(A17) expression resulted in 30
UTR shortening: of the 134 transcripts that showed a significant
shift in CS usage, 103 transcripts showed an induction of the
proximal CS usage (p = 1.6 * 1010; binomial tail; Figure 5C).(F) U2OS cells were transfected with miR-17-19 or control vectors for 96 hr. miR-2
in BJ primary foreskin cells where the miR-17-19 cluster is hardly expressed. Da
(G) Immunoblot showing CCND1 in control and PABPN1kd (#1, #2) cells, with CC
Asterisk: nonspecific band.
(H) U2OS cells were transfectedwithmiRVec-control, miRVec-17-19 (left panel), o
and #2 siRNAs. The relative R/F ratios of CCND1 short (psiC-D1-S) versus full-le
PABPN1 kd significantly reduced miR-17-19-mediated repression of the CCND1
CCND1 30 UTR form from 3-fold to 2-fold (n = 9; mean ± SEM; one-tailed t te
See also Figure S4.Proximal PUI analysis also demonstrated that trePABPN1(A17)
expression resulted in enhanced usage of proximal CSs (Figures
5D and 5E). Importantly, we observed a significant overlap
between the genes that showed 30 UTR shortening in response
to trePABPN1(A17) overexpression and in response to endoge-
nous PABPN1 kd (60 transcripts; p = 1.7 * 107; hypergeometric
tail). These results indicate that trePABPN1 functions in a domi-
nant-negative manner by interacting with WT PABPN1 and
sequestering it to nuclear dots, and its effect on APA is similar
to the effect of inhibiting WT PABPN1 by RNAi.
To study the effect of trePABPN1 function on APA in vivo, we
applied 30Seq to skeletal muscle tissues from an OPMD mouse
model that expresses trePABPN1(A17) (Davies et al., 2005). This
30Seq dataset included samples from OPMD mice aged
20 weeks or 12 months and their matching controls. We de-
tected 10,849 CSs, 55% of which mapped to 30 UTRs. Motif
analysis identified the canonical PAS as themost enriched signal
in the CS regions, and its location distribution sharply peaked at
the expected position 20–25 nt upstream of the mapped CSs
(Figures S6A and S6B). In line with our findings in human cells,
murine muscle tissue expressing the trePABPN1(A17) mut
showed an extensive 30 UTR shortening at both the age of
12 months (Figures 6A–6D) and the age of 20 weeks (Figures
S6C–S6E). In the analysis of the 12-month-old mice, a total of
305 transcripts showed a significant shift in CS usage in the
comparison between trePABPN1(A17) and control muscle tissues
(Table S2B). Strikingly, 273 of them (90%, p = 3.9 * 1049; bino-
mial tail) showed elevated usage of proximal sites in the tre-
PABPN1(A17) mice (Figure 6B). These results detect for the first
time wide-spreading abnormal APA in a model of a human
genetic disorder and further strongly pinpoint PABPN1 as an
important regulator of this gene regulation process.
Assuming that in many cases 30 UTR shortening would atten-
uate miRNA-mediated transcript degradation, we compared
transcript expression levels between the trePABPN1(A17) and
control samples. We found that at the age of 12 months, the
expression of transcripts with enhanced proximal PAS usage
in trePABPN1(A17) mice was significantly elevated in these mice
compared to their expression in the WT controls (Figure 6E). A
similar trend, but with reduced statistical significance, was
observed for the 20-week-old mice (Figure S6F) and in U2OS
cells expressing trePABPN1(A17) (Figure S5).
DISCUSSION
APA is a layer of gene regulation that to date remains largely
unexplored. Yet, it is becoming evident that a large portion of
human genes contain multiple CSs and PASs in their 30 UTRs.0a was detected by qRT-PCR and normalized to GAPDH and tomiR-20a levels
ta are shown as average ± SD.
ND1 ratios (miR-17-19 to control transfected cells) indicated below the blots.
r miRVec-222 (right panel) and reverse transfectedwith control and PABPN1 #1
ngth (psiC-D1-FL) or p27 double mutant (DM) versus WT 30 UTRs are shown.
full-length construct, resulting in a reduction of the relative short/long ratio of
st).
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Figure 5. OPMD-Associated trePABPN1(A17) Induces 30 UTR Shortening
(A) U2OS cells mildly transfected with GFP-trePABPN1(A17) for 2 days (0.8-fold compared with endogenous WT PABPN1, as determined by quantitative analysis
of WCE bands in B, lane 4, upper panel). Cells were fixed and immunostained with PABPN1 antibody.
(B) Immunoprecipitations (a-GFP or control antibody) of WCE from GFP and GFP-trePABPN1(A17) transfected cells were immunoblotted to detect the indicated
proteins with a-PABPN1 (upper panel). a-CCND2 (D2) and a-GFP: controls (middle and lower panels). PABPN1 is present in anti-GFP immunoprecipitations from
cells transfected with trePABPN1(A17)-expressing construct.
(C) Numbers of transcripts with 30 UTR shortening or lengthening in U2OS cells expressing trePABPN1(A17) compared to control cells. (p value was calculated
using binomial tail.)
(D) The median of the proximal PUI distribution as a global measure for the level of proximal CS usage in each sample.
(E) Comparison between the proximal PUI distribution calculated in the trePABPN1(A17) and control U2OS cells. (p value calculated using Wilcoxon test.)
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Therefore, it is conceivable that the majority of human genes are
subjected to APA regulation. The maturation of deep-
sequencing methods specifically designed to probe transcript
30 ends significantly enhances our ability to globally characterize
alternative CSs and PASs and hence appreciate the full scope of
APA regulation under various physiological stresses and patho-
logical conditions. Here, we developed an RNAi screen to iden-
tify APA regulators and pinpointed PABPN1 as an important
player in this process. We have adapted a deep-sequencing
technique, 30Seq, and applied it to obtain genome-wide views
of PABPN1’s role in determination of PAS usage.
PABPN1 Controls Proximal PAS Usage
Previous in vitro data indicated that PABPN1 binds to poly(A)
tails and controls their extension (Ku¨hn et al., 2009). It stimulates
polyadenylation by the PAP enzyme but also restricts polyade-
nylation once the poly(A) tail reaches a certain size (250 nt in
humans). Here, we show that PABPN1 regulates APA by sup-
pressing the usage of weak proximal PASs (Figure 7, upper
and middle panel). This suggests that PABPN1 acts prior to
cleavage and polyadenylation of mRNAs to determine proper
rate of proximal PAS usage.
Our in vitro and in vivo data suggest that PABPN1 directly
interacts with PAS regions and by that competes with the
cleavage and polyadenylation complexes on the recognition of
weak proximal and noncanonical PASs. Whereas PABPN1 is
likely to bind also to canonical PAS regions, the competition
with polyadenylation and cleavage complexes on such regions
is predicted to be much lower due to the significantly stronger
recruitment of the cleavage and polyadenylation machinery to
canonical PAS regions. Our in vitro cleavage assays support
this notion. Canonical distal PAS regions were more active and
less affected by reduced PABPN1 levels than proximal PAS
regions. Nevertheless, our results cannot exclude indirect
effects of PABPN1 on PAS selection, e.g., through PABPN1
association with Pol II (Bear et al., 2003).
PABPN1 and OPMD
AGCG repeat extension in the PABPN1 gene from 6 to 8–13 trip-
lets (trePABPN1) causes OPMD, which is characterized by
progressive degeneration of particular muscles in adults (Tava-
nez et al., 2005). trePABPN1 proteins induce nuclear protein
aggregation and form filamentous nuclear inclusions (Calado
et al., 2000; Thome´ et al., 1997). Our data support the induction
of nuclear inclusion by trePABPN1(A17) and further suggest that
by binding to WT PABPN1 and sequestering it to inclusion
bodies, trePABPN1(A17) dominant negatively affects its WT
protein function (Figure 7, lower panel). Indeed, the global effect
on CS selection that we elicited by ectopic expression of tre-
PABPN1(A17) resembled the effect elicited by PABPN1 kd.
A transgene OPMDmouse model was developed by express-
ing mut trePABPN1(A17) under the control of the muscle-specific
human skeletal actin promoter (Davies et al., 2005). In this mouse
model, the expression of trePABPN1(A17) leads to a dystrophic
phenotype in the presence of two endogenous WT PABPN1
copies and mimics the progressive muscle weakness seen in
OPMD patients. This observation argues as well for a toxic
gain of function for trePABPN1(A17) (Davies et al., 2005).We found in this mouse model a global induction of proximal
PAS usage mediated by trePABPN1(A17). Also, it seems that
aggregates of the mut protein coaggregate with WT PABPN1,
which would result in depletion and reduced activity of WT
PABPN1 in OPMD muscle cells.
Our results imply that OPMD is associated with misregulated
APA, which results in unbalanced formation of alternative
mRNA 30ends. They also predict that OPMD symptoms in hu-
mansmaybe to a certain degree a result of aberrant gene expres-
sion due to a change in 30-end formation. Though our results
predict a change in APA during OPMD development, it could
be expected that endogenously expressed trePABPN1 in
OPMD patients would present a milder APA phenotype com-
pared to the mouse model (due to higher transgene expression)
or compared to experimental conditions in which WT PABPN1
expression is dramatically reduced. To what extent trePABPN1
mutants induce aberrant APA in patient cells, and which genes
and phenotypes are affected, remain to be investigated.
Possible Role of PABPN1 in Proliferation and Cancer?
Regulation of PAS usage and progressive 30 UTR shortening and
lengthening were observed during immune cell reactivation
(Sandberg et al., 2008), cancer progression (Mayr and Bartel,
2009), and development (Ji et al., 2009). To date it is unknown
whether PABPN1 is involved in these processes. Given that
OPMD patients were so far not reported to be at higher risk of
developing cancer and OPMD mouse models are not suscep-
tible to tumor growth, it would be interesting to examine levels
of PABPN1, its posttranscriptional modification status, and its
function in cancer or during normal cellular differentiation.
EXPERIMENTAL PROCEDURES
Cell Culture
U2OS osteosarcoma and HeLa cells and RPE-1 hTERT-immortalized retinal
pigment epithelial cells were maintained in DMEM or RPMI 1640, respectively,
supplemented with 10% FCS in a 5% air-humidified atmosphere at 37C.
Transfections and Luciferase Assay
Transfection constructs were cloned as described in the Extended Experi-
mental Procedures. Cells were transfected with psiCHECK2 constructs
(Fugene6; Roche). After 72 hr, dual luciferase activity assays (Promega)
were performed. Cells were transfected with PABPN1 siRNAs (final concentra-
tion: 25 nM; Dharmafect3; Dharmacon).
Coimmunoprecipitation
GFP-trePABPN1(A17) or GFP was overexpressed in U2OS cells for 2 days and
immunoprecipitated with GammaBind G Sepharose beads (Ge Healthcare)
using a mouse GFP antibody (Roche) or an unrelated mouse Cox-2 antibody
(sc-19999, Santa Cruz Biotechnology). Cell extracts were cleared in lysis
buffer (50 mM HEPES, 150 mM NaCl, 0.5% Nonidet P-40 [pH 7.5], protease
inhibitor [PI; Roche]) and incubated with GFP or Cox-2 antibody overnight
at 4C. Next, the extract/antibody mix was combined with the GammaBind
G Sepharose beads and incubated for 3 hr at 4C. After washing with lysis
buffer (described above), the beads were resuspended in sample buffer and
subjected to immunoblotting.
R-EMSA
Radiolabeled RNA probes (Extended Experimental Procedures) were gener-
ated by in vitro transcription (miRNA probe construction kit; Ambion). RNA
probe (15,000 cpm) was incubated with 50 nM rPABPN1 in 10 ml binding buffer
(50 mM Tris-HCl [pH 8.0], 10% glycerol, 0.2 mg/ml BSA, 0.01% Nonidet P-40,Cell 149, 538–553, April 27, 2012 ª2012 Elsevier Inc. 549
Figure 6. Extensive APA Misregulation in an OPMD Mouse Model
(A) Examples of three genes showing a significant increase in proximal relative to distal CS usage in muscle tissues from 12-month-old trePABPN1(A17) compared
to control WT mice.
(B) Three hundred and five transcripts showed a significant shift in CS usage between trePABPN1(A17) and WT mice, with 90% shifting toward proximal CSs.
(p value was calculated using binomial tail.)
(C) Comparison between the PUI distribution of the proximal CSs in trePABPN1(A17) and WT mice. (p value calculated using Wilcoxon test.)
(D) The median of the proximal PUI distribution as a global measure for proximal CS usage in each sample, turning from negative in WT to positive in tre-
PABPN1(A17) mice.
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Figure 7. A Model for PABPN1’s Mode of Action in
Regulation of APA
Schematic model for PABPN1’s role in suppressing the
usage of proximal weaker PASs (upper and middle
panels). Ectopic expression of trePABPN1(A17) reduces
the endogenousWT PABPN1 function by excluding it from
the soluble nucleoplasm (lower panel).0.5 mM DTT, 100 mM KCl, 2 mM MgCl2) for 15 min at room temperature (RT)
andwas runwith 2 ml loading buffer (50%glycerol, 0.1% bromophenol blue) on
a native gel (6% polyacrylamide [37.5:1], 40% glycerol, and 13 TBE) for 3 hr at
220 V. The gel was exposed to a Phosphor Imaging Plate and developed on
the BAS-2500 system (both Fujifilm).
In Vivo Binding Assay
Cells were grown overnight in medium containing 1 mM 4-thiouridine
(4SU; SigmaAldrich). Next, the cells were irradiated (365 nmUV light crosslink-
ing; 0.15 J/cm2; Stratalinker 2400) and harvested in lysis buffer (50 mMHEPES
[pH 7.5], 140 mM NaCl, 1% Triton X-100, 0.1% NaDeoxycholate, PI
[Roche], RNaseOUT [Invitrogen]). Cleared cell lysates were treated with RNA
fragmentation buffer (Ambion) for 3 min at 70C and incubated with a PABPN1
antibody (2428-1; Epitomics) or an unrelated IgG antibody (sc-2027, Santa
Cruz Biotechnology) overnight at 4C. GammaBind G Sepharose beads (GE
Healthcare) were preblocked with yeast tRNA (Invitrogen) and RNase-free
BSA (Ambion). Next, preblocked G Sepharose beads were combined with
antibody/protein lysate mix and incubated for 4 hr at 4C. After intensive
washing, the beads were resuspended in lysis buffer (with proteinase K)
and incubated for 1 hr at 50C. RNAwas extracted (Trizol; Invitrogen) and sub-(E) Comparison of changes in expression levels in trePABPN1(A17) versus WTmuscles samples (12-mo
containing genes that showed a significant shift toward proximal CSs in the trePABPN1(A17) tissue an
measured in our dataset (p value calculated using Wilcoxon test).
See also Figures S5 and S6 and Table S2B.
Cell 149jected to gene-specific cDNA synthesis and qPCR
(primer: Extended Experimental Procedures).
In Vitro Cleavage Assay
Assay was performed as described by Wahle and Keller
(1994; Extended Experimental Procedures). 1 3 107
HeLa cells were resuspended in 500 ml buffer (10 mM
Tris-HCl [pH 7.8], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
DTT, PI; Roche), homogenized (25G needle), and centri-
fuged at 2000 3 g for 15 min. Nuclei were resuspended
in 200 ml solution (25% glycerol, 20 mM Tris-HCl [pH
7.8], 1.5 mM MgCl2, 0.2 mM EDTA, 0.6 M NaCl, 0.5 mM
DTT, PI; Roche). Capped (Vaccinia capping system; New
England Biolabs) and 32P-labeled RNAs were prepared
with Ambion’s probe construction kit and gel purified.
Cleavage reactions were prepared in 12,5 ml containing
50,000 cpm of labeled RNA, 2 mM DTT, 1.5 mM MgCl2,
0.8 mM 30dATP, 0.1 mg/ml tRNA, 3% PEG 6000, 50 mM
KCl, 20 mM creatine phosphate, 40 U RNaseOUT (Invitro-
gen), and 12.5 ml nuclear extracts, incubated at 30C for
2 hr, and stopped with proteinase K and SDS. RNA was
extracted (Trizol; Invitrogen), precipitated, separated on
a 10% acrylamide-7 M urea gel, and visualized by
autoradiography.
30-End qRT-PCR
Total RNA was extracted (RNeasy Mini kit; QIAGEN), and
3 mg was heat fragmented (fragmentation buffer; Ambion)
for 5 min at 70C. The fragmented total RNA was precipi-
tated, the first cDNA strand synthesized (SuperScript IIIreverse transcriptase; P7-t25-vn oligo-dT primer; Invitrogen), and qRT-PCR
performed as described above (P7-primer; gene-specific forward primers;
Extended Experimental Procedures).
Animal Studies
Animal work was performed under the jurisdiction of appropriate UK Home
Office Licenses.
ACCESSION NUMBERS
Raw sequence data and wig files that summarize read coverage along the
chromosomes (normalized to 10 M mapped reads) are available in the Gene
Expression Omnibus (GEO) database under accession number GSE27452.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
six figures, and six tables and can be found with this article online at
doi:10.1016/j.cell.2012.03.022.nth-old mice) between two sets of transcripts: a target set
d a background (BG) set containing the rest of the genes
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